Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials

Status: Recruiting
Phase: N/A
Diagnosis: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
NCT ID: NCT00487513 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 06-276

 

In order to learn more about follicular lymphoma and anti-cancer vaccines, we are collecting samples from people with this diagnosis. We then hope to make a vaccine from this tissue to help the immune system destroy cancer cells. We plan on keeping samples in the tissue bank indefinitely.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital

Overall PI:
Eric Jacobsen, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Nicole Gallo, 617-582-7970, nicole_gallo@dfci.harvard.edu

Eligibility Criteria

Inclusion Criteria: - Relapsed, refractory or de novo histologically confirmed follicular B-cell lymphoma with accessible lymph nodes, tumor mass or malignant effusion or peripheral blood - 40 years of age or older Exclusion Criteria: - Uncontrolled active infection - HIV or viral Hepatitis infection - Other current malignancies except any in situ cancer or basal or squamous cell carcinoma of the skin - Autoimmune cytopenias
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms